北米の血流感染症検査（BSI検査）の市場規模、シェア、動向分析レポート：製品タイプ別、サンプルタイプ別、技術別、エンドユーザー別、地域別、セグメント別予測、2023年～2030年

北米の血流感染症検査（BSI検査）市場の成長と動向：

Grand View Research, Inc.の新しい調査によると、北米のBSI検査市場規模は2030年までに4億853万米ドルに達する見込みです。

同市場は2023年から2030年にかけてCAGR 3.6％で拡大すると予測されています。高度なBSI検査方法に対する需要の増加、培養に依存しない検査の導入、CROや法医学・研究所の増加などが、BSI検査市場の成長を促進すると予測される主な要因です。

血流感染症（BSI）は、医療経済的にも臨床的にも不利な結果をもたらします。重症敗血症や敗血症性ショック症例のかなりの部分（30～40％）が培養で証明されたBSIに起因すると考えられ、最初の24時間以内に適切な抗菌薬療法が実施されない場合、生存率が急激に低下します。このリスクを軽減するために、臨床医はしばしば正確な病原体の同定を行わずに広域抗菌薬療法に頼っており、耐性病原体の選択と拡散につながっています。

抗菌薬感受性試験による迅速なBSI検出法の導入は、感染制御の実践、治療管理、および臨床的意思決定に革命をもたらす可能性があります。このアプローチは、不必要な抗菌薬処方を減らし、有害転帰の有病率を低下させ、医療環境における資源利用を最適化する可能性を秘めています。

F. Hoffmann-La Roche Ltd.、bioMerieux SA、T2 Biosystems、BD、Cepheidなど、この地域のBSI検査市場の主要企業は、製品能力を強化し、製品提供を促進するために、合併、買収、提携などの戦略的イニシアチブを実施しています。例えば、2023年6月、米国の迅速敗血症検出ソリューションの大手プロバイダーであるT2 Biosystems, Inc.は、Vanderbilt University Medical CenterのLearning Healthcare System（LHS）Platformと協業パートナーシップを確立しました。

この提携の一環として、バンダービルト大学医療センターはFDAが承認したT2Bacteria Panelを臨床の場で統合し、評価します。血液サンプルから直接T2Bacteria Panelを利用することの影響を評価する前向き研究が実施され、血流感染と診断された患者に対する抗生物質の使用と臨床介入の改善に焦点が当てられます。このパートナーシップは、敗血症管理の進歩における重要な前進を示すものであり、医療提供における前向きな変化を推進するという両組織のコミットメントを強調するものです。

北米のBSI検査市場レポート・ハイライト

• 製品別では、ドナーやレシピエントがスクリーニング製品を容易に入手でき、頻繁に購入できることから、試薬・消耗品セグメントが最大の売上シェアを占めました。
• サンプルタイプ別では、自動血液培養システムの発売とその有効性の向上により、血液培養セグメントが市場を独占しました。
• 技術別では、PCRセグメントが2022年に最大の収益シェアを占め、医師や患者の間で最も好まれる技術です。
• 病院・診断センターが2022年のエンドユーザーセグメントをリードしましたが、これは入院件数の増加に起因しています。
• 米国は、有利な償還政策、感染症の高い有病率、大規模な患者プールの存在により、2022年の北米のBSI検査市場を独占しました。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 市場変数、動向、および範囲

• 市場系統の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 市場力学
  • 市場促進要因の分析
  • 市場抑制要因分析
• 業界分析ツール
  • ポーターのファイブフォース分析
  • PESTEL分析
  • COVID-19感染症の影響分析

第4章 北米のBSI検査市場：製品のビジネス分析

• 北米のBSI検査市場：製品の変動分析
• 機器
• 試薬・消耗品

第5章 北米のBSI検査市場：サンプルタイプのビジネス分析

• 北米のBSI検査市場：サンプルタイプの変動分析
• 全血
• 血液培養

第6章 北米のBSI検査市場：技術のビジネス分析

• 北米のBSI検査市場：技術の変動分析
• PCR
• 質量分析
• ISH
• その他

第7章 北米のBSI検査市場：エンドユーザーのビジネス分析

• 北米のBSI検査市場：エンドユーザーの変動分析
• 病院・診断センター
• カスタムラボサービスプロバイダー
• 学術・研究機関
• その他

第8章 北米のBSI検査市場：地域のビジネス分析

• 北米

第9章 北米のBSI検査市場：競合情勢

• 参入企業
• 参入企業の概要
• 財務実績
• 製品のベンチマーク
• 企業の市場シェア分析、2022年
• 戦略マッピング

第10章 アナリストの視点

List of Tables

• Table 1 List of Secondary Sources
• Table 2 List of Abbreviations
• Table 3 North America Bloodstream Infection Testing Market, By Country, 2018 - 2030 (USD Million)
• Table 4 North America Bloodstream Infection Testing Market, By Product, 2018 - 2030 (USD Million)
• Table 5 North America Bloodstream Infection Testing Market, By Sample Type, 2018 - 2030 (USD Million)
• Table 6 North America Bloodstream Infection Testing Market, By Technology, 2018 - 2030 (USD Million)
• Table 7 North America Bloodstream Infection Testing market, by End-user, 2018 - 2030 (USD Million)
• Table 8 U.S. Bloodstream Infection Testing market, by Product, 2018 - 2030 (USD Million)
• Table 9 U.S. Bloodstream Infection Testing market, by Sample Type, 2018 - 2030 (USD Million)
• Table 10 U.S. Bloodstream Infection Testing Market, By Technology, 2018 - 2030 (USD Million)
• Table 11 U.S. Bloodstream Infection Testing market, by End-user, 2018 - 2030 (USD Million)
• Table 12 Canada Bloodstream Infection Testing market, by Product, 2018 - 2030 (USD Million)
• Table 13 Canada Bloodstream Infection Testing market, by Sample Type, 2018 - 2030 (USD Million)
• Table 14 Canada Bloodstream Infection Testing Market, By Technology, 2018 - 2030 (USD Million)
• Table 15 Canada Bloodstream Infection Testing market, by End-user, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Information procurement
• Fig. 3 Primary research pattern
• Fig. 4 Market research approaches
• Fig. 5 Value chain-based sizing & forecasting
• Fig. 6 Market formulation & validation
• Fig. 7 Microscope software, market segmentation
• Fig. 8 Market snapshot, 2022
• Fig. 9 Market Trends & Outlook
• Fig. 10 Market driver relevance analysis (current & future impact)
• Fig. 11 Market restraint relevance analysis (current & future impact)
• Fig. 12 Market challenge relevance analysis (current & future impact)
• Fig. 13 SWOT analysis
• Fig. 14 Porter's five forces analysis
• Fig. 15 Regional marketplace: key takeaways
• Fig. 16 Regional outlook, 2022 & 2030
• Fig. 17 North America bloodstream infection testing market: region movement analysis.
• Fig. 18 North America bloodstream infection testing market, 2018 - 2030 (USD Million)
• Fig. 19 U.S. key country dynamics
• Fig. 20 U.S. bloodstream infection testing market, 2018 - 2030 (USD Million)
• Fig. 21 Canada key country dynamics
• Fig. 22 Canada bloodstream infection testing market, 2018 - 2030 (USD Million)

North America Bloodstream Infection Testing Market Growth & Trends:

The North America bloodstream infection testing market size is expected to reach USD 408.53 million by 2030, according to a new study by Grand View Research, Inc.. The market is expected to expand at a CAGR of 3.6% from 2023 to 2030. Increasing demand for advanced bloodstream infection testing methods, the introduction of culture-independent tests, and a rising number of CROs and forensic & research laboratories are among the major factors expected to drive growth in the bloodstream infection testing market.

Bloodstream infections (BSIs) are associated with adverse health-economic and clinical outcomes. A substantial portion (30-40%) of severe sepsis and septic shock cases can be attributed to culture-proven BSIs, which exhibit a sharp decline in survival rates if appropriate antimicrobial therapy is not administered within the first 24 hours. To mitigate this risk, clinicians often resort to broad-spectrum antimicrobial therapy without precise pathogen identification, leading to the selection and spread of resistant pathogens.

Implementing rapid BSI detection methods with antibiotic susceptibility testing can revolutionize infection control practices, therapeutic management, and clinical decision-making. This approach has the potential to reduce unnecessary antimicrobial prescriptions, lower the prevalence of adverse outcomes, and optimize resource utilization in healthcare settings.

The key players in the regional bloodstream infection testing market, such as F. Hoffmann-La Roche Ltd., bioMerieux SA, T2 Biosystems, BD, Cepheid, etc., are implementing strategic initiatives such as mergers, acquisitions, and collaborations to enhance product capabilities and promote their offerings. For instance, in June 2023, T2 Biosystems, Inc., a major provider of rapid sepsis detection solutions in the U.S., established a collaborative partnership with Vanderbilt University Medical Center's Learning Healthcare System (LHS) Platform.

As part of the collaboration, Vanderbilt University Medical Center will integrate and assess the FDA-cleared T2Bacteria Panel in a clinical setting. A prospective study will be conducted to evaluate the impact of utilizing the T2Bacteria Panel directly from blood samples, focusing on improving antibiotic usage and clinical interventions for patients diagnosed with bloodstream infections. This partnership indicates a significant step forward in advancing sepsis management and underscores both organizations' commitment to driving positive change in healthcare delivery.

North America Bloodstream Infection Testing Market Report Highlights:

• Based on the product, the reagents and consumables segment accounted for the largest revenue share owing to the easy availability and frequent purchase of screening products for donors and recipients
• Based on sample type, the blood culture segment dominated the market owing to the launch of automated blood culture systems and their improved efficacy
• Based on technology, the PCR segment held the largest revenue share in 2022 and is the most preferred technology among doctors and patients
• Hospital and diagnostic centers led the end-user segment in 2022, which is attributable to the increasing number of hospitalizations
• The U.S. dominated the North American bloodstream infection testing market in 2022 due to favorable reimbursement policies, the high prevalence of infections, and the presence of a large patient pool in the country

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
  • 1.1.1. Segment Definitions
    • 1.1.1.1. Sample Type segment
    • 1.1.1.2. Product segment
    • 1.1.1.3. Technology segment
    • 1.1.1.4. End-user segment
• 1.2. Regional Scope
• 1.3. Estimates and Forecast Timeline
• 1.4. Objectives
  • 1.4.1. Objective - 1
  • 1.4.2. Objective - 2
  • 1.4.3. Objective - 3
• 1.5. Research Methodology
• 1.6. Information Procurement
  • 1.6.1. Purchased Database
  • 1.6.2. GVR's Internal Database
  • 1.6.3. Secondary Sources
  • 1.6.4. Primary research
• 1.7. Information or Data Analysis
  • 1.7.1. Data Analysis Models
• 1.8. Market Formulation & Validation
• 1.9. Model Details
  • 1.9.1. Commodity Flow Analysis
• 1.10. List of Secondary Sources
• 1.11. List of Abbreviations

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Product and Sample Type Snapshot
• 2.3. Technology and End-user Snapshot
• 2.4. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increasing prevalence of infectious diseases
    • 3.2.1.2. Technological Advancements in Bloodstream infection testing
    • 3.2.1.3. Growing Initiatives for blood donations campaign
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. High Diagnosis Cost and Lower Investments in Underdeveloped Countries
• 3.3. Industry Analysis Tools
  • 3.3.1. Porter's Five Forces Analysis
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. North America Bloodstream Infection Testing Market: Product Business Analysis

• 4.1. North America Bloodstream Infection Testing Market: Product Movement Analysis
• 4.2. Instruments
  • 4.2.1. Instruments Market, 2018 - 2030 (USD Million)
• 4.3. Reagents and Consumables
  • 4.3.1. Reagents and Consumables Market, 2018 - 2030 (USD Million)

Chapter 5. North America Bloodstream Infection Testing Market: Sample Type Business Analysis

• 5.1. North America Bloodstream Infection Testing Market: Sample Type Movement Analysis
• 5.2. Whole Blood
  • 5.2.1. Whole Blood Market, 2018 - 2030 (USD Million)
• 5.3. Blood Culture
  • 5.3.1. Blood Culture Market, 2018 - 2030 (USD Million)

Chapter 6. North America Bloodstream Infection Testing Market: Technology Business Analysis

• 6.1. North America Bloodstream Infection Testing Market: Technology Movement Analysis
• 6.2. PCR
  • 6.2.1. PCR Market, 2018 - 2030 (USD Million)
• 6.3. Mass Spectroscopy
  • 6.3.1. Mass Spectroscopy Market, 2018 - 2030 (USD Million)
• 6.4. In Situ Hybridization
  • 6.4.1. In Situ Hybridization Market, 2018 - 2030 (USD Million)
• 6.5. Others
  • 6.5.1. Others Market, 2018 - 2030 (USD Million)

Chapter 7. North America Bloodstream Infection Testing Market: End-User Business Analysis

• 7.1. North America Bloodstream Infection Testing Market: End-User Movement Analysis
• 7.2. Hospitals & Diagnostic Centers
  • 7.2.1. Hospitals & Diagnostics Centers Market, 2018 - 2030 (USD Million)
• 7.3. Custom Laboratory Service Providers
  • 7.3.1. Custom Laboratory Service Providers Market, 2018 - 2030 (USD Million)
• 7.4. Academic & Research Institutes
  • 7.4.1. Academic & Research Institutes Market, 2018 - 2030 (USD Million)
• 7.5. Others
  • 7.5.1. Others Market, 2018 - 2030 (USD Million)

Chapter 8. North America Bloodstream Infection Testing Market: Regional Business Analysis

• 8.1. North America
  • 8.1.1. SWOT Analysis
  • 8.1.2. North America Bloodstream Infection Testing Market, 2018 - 2030 (USD Million)
  • 8.1.3. U.S.
    • 8.1.3.1. Key Country Dynamics
    • 8.1.3.2. Target Disease Prevalence
    • 8.1.3.3. Competitive Scenario
    • 8.1.3.4. Regulatory Framework
    • 8.1.3.5. U.S. Bloodstream Infection Testing Market, 2018 - 2030 (USD Million)
  • 8.1.4. Canada
    • 8.1.4.1. Key Country Dynamics
    • 8.1.4.2. Target Disease Prevalence
    • 8.1.4.3. Competitive Scenario
    • 8.1.4.4. Regulatory Framework
    • 8.1.4.5. Canada Bloodstream Infection Testing Market, 2018 - 2030 (USD Million)

Chapter 9. North America Bloodstream Infection Testing Market: Competitive Landscape

• 9.1. Participant Categorization
  • 9.1.1. bioMerieux SA
    • 9.1.1.1. Overview
    • 9.1.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.1.1.3. Product Benchmarking
    • 9.1.1.4. Strategic Initiatives
  • 9.1.2. BD
    • 9.1.2.1. Overview
    • 9.1.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.1.2.3. Product Benchmarking
    • 9.1.2.4. Strategic Initiatives
  • 9.1.3. Cepheid
    • 9.1.3.1. Overview
    • 9.1.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.1.3.3. Product Benchmarking
    • 9.1.3.4. Strategic Initiatives
  • 9.1.4. Seegene Inc.
    • 9.1.4.1. Overview
    • 9.1.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.1.4.3. Product Benchmarking
    • 9.1.4.4. Strategic Initiatives
  • 9.1.5. Abbott
    • 9.1.5.1. Overview
    • 9.1.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.1.5.3. Product Benchmarking
    • 9.1.5.4. Strategic Initiatives
  • 9.1.6. F. Hoffmann-La Roche Ltd
    • 9.1.6.1. Overview
    • 9.1.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.1.6.3. Product Benchmarking
    • 9.1.6.4. Strategic Initiatives
  • 9.1.7. Siemens Healthcare Limited
    • 9.1.7.1. Overview
    • 9.1.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.1.7.3. Product Benchmarking
    • 9.1.7.4. Strategic Initiatives
  • 9.1.8. Luminex Corporation
    • 9.1.8.1. Overview
    • 9.1.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.1.8.3. Product Benchmarking
    • 9.1.8.4. Strategic Initiatives
  • 9.1.9. Bruker
    • 9.1.9.1. Overview
    • 9.1.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.1.9.3. Product Benchmarking
    • 9.1.9.4. Strategic Initiatives
  • 9.1.10. Accelerate Diagnostics, Inc.
    • 9.1.10.1. Overview
    • 9.1.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.1.10.3. Product Benchmarking
    • 9.1.10.4. Strategic Initiatives
• 9.2. Participant's Overview
• 9.3. Financial Performance
• 9.4. Product Benchmarking
• 9.5. Company Market Share Analysis, 2022
• 9.6. Strategy Mapping
  • 9.6.1. Expansion
  • 9.6.2. Acquisition
  • 9.6.3. Product/Service Launch
  • 9.6.4. Others

Chapter 10. Analyst View